Podcast
MSL Talk: Tom Caravela, Chris Castin
All about Job Offers and what to be aware of
Summary
E66 • Aug 17, 2021 • 41 mins
In this episode, Tom Caravela welcomes Anthony Greco to discuss job offer negotiations. Anthony shares insights on clear communication and understanding legal aspects during compensation discussions. They explore the risks of over-negotiation and emphasize early talks on compensation. The conversation covers negotiable elements like sign-on bonuses and long-term incentives. Anthony offers guidance on navigating non-compete and non-solicitation agreements, providing legal advice and identifying red flags in employment agreements. The episode concludes with reflections on the candidate's experience during the hiring process.
Anthony Greco, Talent Acquisition Lead at BMS discusses what you need to know about job offers and how to properly handle them.
Anthony shares….
👉 What should be included in an Offer Letter
👉 How to best negotiate a Job Offer
👉 Is it true to “Never Accept the First Offer”?
👉 How do sign on bonuses work and when can you expect one
👉 What does “At Will Employment” mean
👉 How to handle a “non compete” and why it differs from a “non solicitation”
job offer negotiations, compensation discussions, employment agreements, non-compete agreements, sign-on bonuses
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Chris Castin
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official